Growth in this market is driven by the rising global incidence of chronic diseases, increasing vaccine development to address the challenge of antimicrobial resistance, and technological advancements in ELISpot and FluoroSpot assay kits and analyzers.
The ELISpot and FluoroSpot market is projected to reach USD 287 million by 2023 from USD 135 million in 2018, at a CAGR of 16.2% during the forecast period.
Download Free Brochure - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=124350584
“Assay Kits are expected to account for the largest share of the market in 2018”
By product type, the ELISpot and FluoroSpot market is segmented into assay kits, analyzers, and ancillary products. The assay kits segment accounted for the largest share in 2018, and this trend is expected to continue during the forecast period. The rising incidence of chronic diseases and technological advancements are driving the growth of this product segment.
“Increasing use of ELISpot kits in diagnostic applications in 2018”
Based on the applications, the ELISpot and FluoroSpot market is segmented into diagnostic and research applications. The diagnostics applications segment is further classified into infectious diseases and transplants. In 2018, the diagnostic segment is expected to account for the larger share of the market. The large share of this segment is attributed to the rising global prevalence of infectious diseases and the increasing use of ELISpot kits for disease diagnosis.
Get Free Sample Report for further information - https://www.marketsandmarkets.com/requestsampleNew.asp?id=124350584
Key Market Players
Some of the prominent players in the ELISpot and FluoroSpot are Oxford Immunotec (UK), Cellular Technologies (US), Mabtech (Sweden), Becton, Dickinson and Company (US), and Abcam (UK).
Oxford Immunotec is the leading player in the ELISpot and FluoroSpot market. The company focuses on the development of diagnostic kits for the early detection of diseases such as TB and tick-borne diseases. The company has its presence across the globe and to maintain and improve its presence in the market; Oxford Immunotec adopted both organic as well as inorganic strategies. The company also invests a significant amount on research and development activities. In 2017, it spent around 16% of its revenue on R&D activities, which is higher than most of its counterparts.
Cellular Technology Limited (CTL) is among the pioneers of the ELISpot and FluoroSpot assays. The company developed the first ELISpot analyzers and has been leading the analyzers market ever since. It also offers ELISpot and FluoroSpot kits for detection of multiple analytes. The company’s assay kits are available for the detection of cytokines, antibodies as well as other analytes such as granzymes. The analyzers from CTL are able to detect up to 8 colors.
Key questions addressed in the report:
- What are the growth opportunities in the ELISpot and FluoroSpot market across major regions in the future?
- Emerging countries have immense opportunities for the growth and adoption of ELISpot and FluoroSpot products. Will this scenario continue during the next five years?
- Where will all the advancements in products offered by various companies take the industry in the mid- to long-term?
- What are the various ELISpot and FluoroSpot product types and their respective market shares in the overall market?
- What are the new trends and advancements in the ELISpot and FluoroSpot market?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst